Lexaria Bioscience (LEXX) Total Current Liabilities (2011 - 2026)
Lexaria Bioscience (LEXX) posted Total Current Liabilities of $383412.0 for Q2 2026, up 78.6% sequentially from $214671.0 in Q1 2026, and down 74.24% YoY from $1.5 million in Q2 2025.
Lexaria Bioscience (LEXX) Total Current Liabilities (2011 - 2026) Analysis & Trends
Lexaria Bioscience has reported Total Current Liabilities for 16 years, with the latest figure at $383412.0 in Q2 2026.
- Quarterly Total Current Liabilities fell 74.24% year-over-year to $383412.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $383412.0 (down 74.24% YoY) and the FY2025 annual result came in at $1.5 million, up 35.84% from the prior year.
- Total Current Liabilities climbed to $383412.0 in Q2 2026 per LEXX's latest filing, from $214671.0 in the prior quarter.
- Over five years, Total Current Liabilities peaked at $1.8 million in Q1 2025 and troughed at $81717.0 in Q1 2024.
- A 5-year average of $611823.7 and a median of $274627.5 in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Current Liabilities jumped 2130.16% in 2025, then sank 88.22% in 2026.
- Over 5 years, Total Current Liabilities stood at $281520.0 in 2022, then plunged by 55.77% to $124523.0 in 2023, then soared by 139.15% to $297798.0 in 2024, then surged by 389.1% to $1.5 million in 2025, then sank by 73.68% to $383412.0 in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $383412.0, $214671.0, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 383,412.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 383,412.00 |
| Feb 28, 2026 | 214,671.00 |
| Nov 30, 2025 | 1.46 Mn |
| Aug 31, 2025 | 1.49 Mn |
| May 31, 2025 | 1.49 Mn |
| Feb 28, 2025 | 1.82 Mn |
| Nov 30, 2024 | 297,798.00 |
| Aug 31, 2024 | 1.10 Mn |
| May 31, 2024 | 156,048.00 |
| Feb 29, 2024 | 81,717.00 |
| Nov 30, 2023 | 124,523.00 |
| Aug 31, 2023 | 267,735.00 |
| May 31, 2023 | 1.06 Mn |
| Feb 28, 2023 | 223,131.00 |
| Nov 30, 2022 | 281,520.00 |
| Aug 31, 2022 | 194,036.00 |
| May 31, 2022 | 206,826.00 |
| Feb 28, 2022 | 165,543.00 |
| Nov 30, 2021 | 237,699.00 |
| Aug 31, 2021 | 153,276.00 |